BlackRock Advisors’s GALENA BIOPHARMA INC COM RXII Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-106,061
| Closed | -$37K | – | 3817 |
|
|
2016
Q3 | $37K | Buy |
106,061
+21,790
| +26% | +$7.6K | ﹤0.01% | 3331 |
|
|
2016
Q2 | $39K | Sell |
84,271
-2,620
| -3% | -$1.21K | ﹤0.01% | 3290 |
|
|
2016
Q1 | $118K | Buy |
86,891
+11,922
| +16% | +$16.2K | ﹤0.01% | 2844 |
|
|
2015
Q4 | $110K | Sell |
74,969
-29,416
| -28% | -$43.2K | ﹤0.01% | 2880 |
|
|
2015
Q3 | $165K | Sell |
104,385
-3,256
| -3% | -$5.15K | ﹤0.01% | 2832 |
|
|
2015
Q2 | $183K | Buy |
107,641
+12,363
| +13% | +$21K | ﹤0.01% | 2841 |
|
|
2015
Q1 | $132K | Buy |
95,278
+25,592
| +37% | +$35.5K | ﹤0.01% | 2911 |
|
|
2014
Q4 | $105K | Sell |
69,686
-3,291
| -5% | -$4.96K | ﹤0.01% | 3017 |
|
|
2014
Q3 | $150K | Sell |
72,977
-1,311
| -2% | -$2.69K | ﹤0.01% | 2779 |
|
|
2014
Q2 | $227K | Sell |
74,288
-10,021
| -12% | -$30.6K | ﹤0.01% | 2559 |
|
|
2014
Q1 | $211K | Buy |
84,309
+5,729
| +7% | +$14.3K | ﹤0.01% | 2611 |
|
|
2013
Q4 | $390K | Buy |
78,580
+13,700
| +21% | +$68K | ﹤0.01% | 2224 |
|
|
2013
Q3 | $148K | Buy |
64,880
+11,454
| +21% | +$26.1K | ﹤0.01% | 2718 |
|
|
2013
Q2 | $119K | Buy |
+53,426
| New | +$119K | ﹤0.01% | 2780 |
|
BlackRock Advisors's RXII Position: Q4 2016 in Review
BlackRock Advisors sold out of GALENA BIOPHARMA INC COM (RXII) in Q4 2016, closing a stake of 106,061 shares — an estimated $37K sold.
BlackRock Advisors first reported a position in RXII in Q2 2013 and held it in 14 quarters. The position peaked at $390K in Q4 2013. 0 funds tracked by Wall St. Rank hold RXII as of Q4 2016.
- BlackRock Advisors reported no remaining GALENA BIOPHARMA INC COM position as of Q4 2016 after selling out during the quarter.
- BlackRock Advisors sold 106,061 GALENA BIOPHARMA INC COM shares in Q4 2016, an estimated $37K.
- BlackRock Advisors first reported a position in GALENA BIOPHARMA INC COM in Q2 2013 and held it in 14 quarters.
- BlackRock Advisors's GALENA BIOPHARMA INC COM position peaked at $390K in Q4 2013.
- 0 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q4 2016.
Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.